Improving the outcome for children with cancer: Development of targeted new agents

Area of Science:

• Pediatric Oncology
• Cancer Therapeutics
• Drug Development

Background:

• Childhood cancer survival rates have exceeded 80% over 60 years, yet it remains a leading cause of pediatric disease-related death.
• Significant short- and long-term toxicities persist for the majority of children undergoing cancer treatment.
• Targeted therapies present a promising avenue for more effective and less toxic pediatric cancer treatment.

Purpose of the Study:

• To review the progress and challenges in developing targeted agents for pediatric cancer.
• To highlight lessons learned from early studies of targeted therapies in children.
• To emphasize the need for continued investment in pediatric cancer drug discovery and development.

Main Methods:

• Review of existing literature on targeted therapies in pediatric oncology.
• Analysis of outcomes and adverse event profiles from clinical studies.
• Discussion of challenges in pediatric drug formulation and development.

Main Results:

• Targeted agents, like imatinib mesylate, have transformed outcomes in specific pediatric leukemias.
• Studies have improved understanding of drug toxicity profiles in children.
• Pediatric-specific formulations and reliance on adult cancer indications pose development challenges.

Conclusions:

• Pediatric cancer research infrastructure is poised to advance novel treatments for rare childhood cancers.
• Increased investment in target discovery and validation is essential for developing new, effective pediatric cancer therapies.
• Collaborative efforts are key to overcoming challenges in pediatric drug development.